Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension

NCT00702221 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped Dose limiting adverse effects

Conditions

Hypertension
Cardiovascular Disease

Interventions

BIOLOGICAL: Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant
BIOLOGICAL: CoVaccine HT™ adjuvant

Sponsor

BTG International Inc.

Collaborators

[object Object]